Browse by Condition

From FDA-approved GLP-1 medications to investigational compounds—what the evidence actually shows about appetite, metabolism, and body composition.

Managing inflammation, optimizing tissue repair, and accelerating return to performance. From BPC-157 to FDA-approved growth hormone.

The transition when ovarian estrogen production ends. Peptide research addresses bone loss, body composition, cognitive changes, and sexual health.

Where cartilage biology meets inflammatory signaling and connective tissue repair. One FDA-approved option and several under investigation.

The brain is where peptide research promises the most and has proved the least. Here is exactly where the evidence stands.

Collagen loss, oxidative damage, and cellular senescence. From topical copper peptides to injectable growth hormone secretagogues.

Growth hormone secretagogues and their connection to slow-wave sleep architecture. One controlled study, several mechanistic arguments, and honest gaps.

Vascular function, hormonal signaling, and neurochemistry. From an FDA-approved peptide to compounds still in clinical trials.

The gut is where peptide research has its strongest mechanistic story—and its widest gap between preclinical promise and clinical proof.

Where the immune system attacks the body’s own tissues. Thymic peptides show genuine clinical history; others remain early-stage.

Neurological, hormonal, and vascular—the complexity of female sexual health is reflected in the peptide research landscape.

More FDA-approved treatments than almost any cosmetic condition—and peptides aren’t among them. Here is what the research actually shows.